Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Krejs, GJ.
Metabolic benefits associated with sibutramine therapy.
Int J Obes Relat Metab Disord. 2002; 26 Suppl 4(1):S34-S37
Doi: 10.1038/sj.ijo.0802217
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Krejs Günter Josef
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Sibutramine-induced weight loss and weight maintenance lead to clinically relevant reductions in risk factors associated with the metabolic syndrome. Treatment with the drug decreases visceral fat, improves lipid levels, decreases glycosylated haemoglobin and decreases uric acid concentrations. Sibutramine is effective in achieving weight loss in patients with type 2 diabetes but weight loss occurs more slowly than in non-diabetic patients. The criteria for predicting response to treatment in uncomplicated patients may not be appropriate to those with type 2 diabetes. Furthermore, it is important to set realistic goals for weight loss in type 2 diabetes to avoid the risk of denying effective treatment to patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Adipose Tissue - pathology
- Appetite Depressants - therapeutic use
- Cyclobutanes - therapeutic use
- Diabetes Mellitus - blood Diabetes Mellitus - drug therapy
- Humans -
- Lipids - blood
- Obesity -
- Weight Loss - drug effects
- Find related publications in this database (Keywords)
- sibutramine
- type 2 diabetes
- metabolic syndrome
- lipids
- uric acid